Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample. PLoS ONE, 2021.

publi

(2021) Journal , vol. 16, no. 10, e0258093

Jean-Pierre Boissel, David Pérol, Hervé Décousus, Ingrid Klingmann, Marc Hommel

Use of a Multiscale NSCLC Tumor Heterogeneity Model to predict Tumor Growth under Gefitinib

poster

(2021), IASLC WCLC, Digital

Adèle L'Hostis

Multiscale NSCLC Tumor Growth Knowledge Based Model Reproduces Tumor Non Progression under Gefitinib

poster

(2021), IASLC WCLC, Digital

Adèle L'Hostis

In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production

poster

(2021), PAGE meeting, Digital

B. Martin, E. Courcelles, A. L’Hostis, L. Etheve, E. Bechet, N. Ceres, E. Jacob, E. Peyronnet, B. M.W. Illigens, M. Hommel, J.P. Boissel

Possible Contexts of Use for In Silico trials methodologies: a consensus- based review

publi

(2021) IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, ,

Marco Viceconti, Luca Emili, Payman Afshari, Eulalie Courcelles, Cristina Curreli, Nele Famaey, Liesbet Geris, Marc Horner, Maria Cristina Jori, Alexander Kulesza, Axel Loewe, Michael Neidlin, Markus Reiterer, Cecile F. Rousseau, Giulia Russo, Simon J. Sonntag, Emmanuelle M. Voisin, and Francesco Pappalardo

Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility

publi

(2021) CPT: Pharmacometrics & Systems Pharmacology, 00:1–22,

Flora T. Musuamba, Ine Skottheim Rusten, Raphaëlle Lesage, Giulia Russo, Roberta Bursi, Luca Emili, Gaby Wangorsch, Efthymios Manolis, Kristin E. Karlsson, Alexander Kulesza, Eulalie Courcelles, Jean-Pierre Boissel, Cécile F. Rousseau, Emmanuelle M. Voisin, Rossana Alessandrello, Nuno Curado, Enrico Dall’ara, Blanca Rodriguez, Francesco Pappalardo, Liesbet Geris

Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges.

publi

(2020) CPT: Pharmacometrics & Systems Pharmacology, vol. 9 issue 4, pp 195-197

Flora T. Musuamba Roberta Bursi Efthymios Manolis Kristin Karlsson Alexander Kulesza Eulalie Courcelles Jean‐Pierre Boissel Raphaëlle Lesage Cécile Crozatier Emmanuelle M. Voisin Cécile F. Rousseau Thierry Marchal Rossana Alessandrello and Liesbet Geris.

An in silico disease model for the development of FXR agonist EYP001 as a therapy for HBV infection.

poster

(2019), AASLD - The Liver Meeting, Boston (USA)

Claudio Monteiro, Lara Bruezière, Samuel Laheux, Marc Hommel, Pauline Radreau, Elise Roy, Raphaël Darteil, Patrice André, Jean-Pierre Boissel, Jacky Vonderscher and Pietro Scalfaro.

A regulatory landscape shift for in silico clinical trials

publi

(2019) Regulatory Rapporteur, vol. 16, no. 11, pp. 18-21

Cécile F Rousseau, Cécile Crozatier, David A duVerle, Marc Buyse, Susan E Carter, Emmanuelle M Voisin, François-Henri Boissel

In silico exploration of immunotherapeutics combinations in lymphoma

poster

(2018), ICSB, Lyon (France)

Lara Brueziere, Adèle L’Hostis, Eulalie Landèche, Emmanuelle Bechet, Polina Kurbatova, Loïc Etheve, Jean-Pierre Boissel.

A logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism

poster

(2018), ICSB, Lyon (France)

Lara Brueziere, Eliott Tixier, Elise Roy, Arnaud Poret, Claudio Monteiro, Pietro Scalfaro, Jean-Pierre Boissel.

An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a.

poster

(2018), PAGE meeting, Montreux (Switzerland)

Claudio Monteiro, Evgueni Jacob, Bastien Martin, Samuel Laheux, Diane Sampson, Elise Roy, Jacky Vonderscher, Pietro Scalfaro, Patrice André, Jean-Pierre Boissel.

Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis

publi

(2015) Comptes Rendus Biologies, vol. 338, no. 10, pp. 635-642

Claudio Monteiro, Jean-Pierre Boissel, François Gueyffier, Gustavo Olivera-Botello

Bridging Systems Medicine and Patient Needs

publi

(2015) CPT: Pharmacometrics & Systems Pharmacology, vol. 4, no. 3, pp. 135-145

J-P Boissel, C Auffray, D Noble, L Hood, F-H Boissel

Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population

publi

(2014) Journal of The Royal Society Interface , vol. 11, no. 100, pp. 20140867-20140867

R. Kahoul, F. Gueyffier, E. Amsallem, M. Haugh, I. Marchant, F.-H. Boissel, J.-P. Boissel

Prediction of chronic lung allograft dysfunction: a systems medicine challenge

publi

(2014) European Respiratory Journal, vol. 43, no. 3, pp. 689-693

C. Pison, A. Magnan, K. Botturi, M. Seve, S. Brouard, B. J. Marsland, F. Ernst, T. Paprotka, K. Deplanche, A. Fritz, V. Siroux, J.-P. Boissel, P. A. Corris, C. Auffray, L. P. Nicod, on behalf of the SysCLAD consortium

Effect Model Law: An Approach for the Implementation of Personalized Medicine

publi

(2013) Journal of Personalized Medicine , vol. 3, no. 3, pp. 177-190

Jean-Pierre Boissel, Riad Kahoul, Draltan Marin, François-Henri Boissel

Towards personalized medicine: exploring the consequences of the effect model-based approach

publi

(2011) Personalized Medicine, vol. 8, no. 5, pp. 581-586

Jean-Pierre Boissel, Riad Kahoul, Emmanuel Amsallem, François Gueyffier, Margaret Haugh, François-Henri Boissel

Julie

Is here to answer your questions or requests.

Do you have any questions for me?

If you want to join the team, please visit our careers section to see all vacancies available

Select a team please
First name is required
Last name is required
Job title is required
Company is required
Email is not valid
Message is required